Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference?

被引：0

作者：

Landi, Lorenza ^{[1
]}

Cappuzzo, Federico ^{[1
]}

机构：

[1] Osped Civile Livorno, Ist Toscano Tumori, I-57100 Livorno, Italy

来源：

JOURNAL OF THORACIC DISEASE | 2012年 / 4卷 / 02期

关键词：

CELL LUNG-CANCER; 1ST-LINE TREATMENT; OPEN-LABEL; CHEMOTHERAPY; MULTICENTER; ERLOTINIB; GEFITINIB;

D O I：

10.3978/j.issn.2072-1739.2012.03.04

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页码：226 / 228

页数：3

共 50 条

[21] Outcomes of TKI Treatment in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Real-World Study in Argentina
Kaen, D.
Tsou, F.
Lupinacci, L.
Puparelli, C.
Minatta, J.
Rizzo, M.
Berutti, S.
Di Giovanni, R.
Ferreira, Y.
Recondo, G.
Carranza, O.
Flores, M.
Aman, E.
Di Mario, G.
Pini, A.
Castagneris, N.
Roa, M.
Enrico, D.
Martin, C.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S667 - S668
[22] Efficacy and Safety of Cytotoxic Drug Chemotherapy After First-Line EGFR-TKI in Elderly Patients with NSCLC Harboring Sensitive EGFR Mutations
Yamada, Y.
Imai, H.
Sugiyama, T.
Minemura, H.
Kaira, K.
Kanazawa, K.
Kasai, T.
Kaburagi, T.
Minato, K.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S908 - S908
[23] Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations
Takeyasu, Yuki
Yoshida, Tatsuya
Masuda, Ken
Matsumoto, Yuji
Shinno, Yuki
Okuma, Yusuke
Goto, Yasushi
Horinouchi, Hidehito
Yamamoto, Noboru
Ohe, Yuichiro
JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (02):
[24] Study of anlotinib combined with icotinib as the first-line treatment in NSCLC patients harboring activating EGFR mutations: Updated results of ALTER-L004
Huang, D.
Zhong, D.
Zhang, C.
Zhang, Y.
Shang, Y.
Wang, L.
ANNALS OF ONCOLOGY, 2021, 32 : S969 - S969
[25] A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinonna harboring EGFR mutations
Kim, Dong-Wan
Lee, Se-Hoon
Lee, Jong Seok
Lee, Myung Ah
Kang, Jin Hyoung
Kim, Si Young
Shin, Sang Won
Kim, Hoon-Kyo
Heo, Dae Seog
LUNG CANCER, 2011, 71 (01) : 65 - 69
[26] A phase I / I to find optimal dose of Erlotinib(RE) in only patients with lung cancer harboring EGFR sensitive mutations
Yuichiro, Takeda
Naoki, Ishizuka
Kazumi, Sano
Haruhito, Sugiyama
CANCER SCIENCE, 2018, 109 : 901 - 901
[27] Real World Analysis Afatinib as a First Line Treatment Patients with Advanced Stage Non-small Cell Lung Cancer Harboring Uncommon EGFR Mutations
Pham, L. V.
Nguyen, H. M.
Le, A. T.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S336 - S336
[28] A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations
Wang, Pingli
Cao, Liming
Tian, Panwen
Ren, Shengxiang
Miao, Liyun
Zhou, Chengzhi
Fan, Yun
Li, Yuping
Lv, Dongqing
Zhao, Xin
Yang, Mei
Zhu, Chaonan
Yu, Bing
Xu, June
Song, Yong
Wang, Kai
CANCER COMMUNICATIONS, 2023, 43 (09) : 1059 - 1063
[29] Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR–TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations
Hisao Imai
Hiroyuki Minemura
Tomohide Sugiyama
Yutaka Yamada
Kyoichi Kaira
Kenya Kanazawa
Takashi Kasai
Takayuki Kaburagi
Koichi Minato
Cancer Chemotherapy and Pharmacology, 2018, 82 : 119 - 127
[30] First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
Sequist, Lecia V.
Martins, Renato G.
Spigel, David
Grunberg, Steven M.
Spira, Alexander
Jaenne, Pasi A.
Joshi, Victoria A.
McCollum, David
Evans, Tracey L.
Muzikansky, Alona
Kuhlmann, Georgiana L.
Han, Moon
Goldberg, Jonathan S.
Settleman, Jeffrey
Iafrate, A. John
Engelman, Jeffrey A.
Haber, Daniel A.
Johnson, Bruce E.
Lynch, Thomas J.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) : 2442 - 2449

← 1 2 3 4 5 →